Navigation Links
CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007
Date:2/7/2008

First Year of Growth in Past Three Years and Fourth Consecutive Quarterly

Revenue Increase Over Prior Year

SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) Impedance Cardiography (ICG) technology, today reported financial results for its fourth quarter and fiscal 2007. Operating results are for the ICG business and do not include results for Vermed which was sold on August 31, 2007.

Key Financial and Operating Results for Fourth Quarter 2007 Compared with Fourth Quarter 2006
-- Net ICG sales increased 8% to $6.2 million, up from $5.7 million

-- International sales increased 57% to $1.0 million, up from $633,000

-- ICG sensor revenue increased 13% to $1.7 million, or 28% of total

sales, up from $1.5 million

-- ICG monitor sales increased 11% to 174 units, 100 of which were BioZ Dx

systems, 16 BioZ monitors, and 58 Medis ICG monitors, up from 157 ICG

monitors

-- ICG gross profit margin improved slightly to 65%

Key Financial and Operating Results of Fiscal 2007 Compared with Fiscal 2006
-- Net ICG sales increased 10% to $21.9 million, up from $19.8 million

-- ICG sensor revenue increased 8% to $6.7 million, or 31% of total sales,

up from $6.2 million

-- 542 ICG monitors sold, up 9% from 499 monitors

-- Nearly 7,800 ICG monitors and modules sold to date, up 11% from one

year ago

-- ICG gross profit margin was 68%, up from 62%

-- Operating loss was $4.8 million, an improvement of $3.0 million, or 38%

-- Operating cash use of $1.1 million, an improvement of $931,000, or 47%

-- Cash, cash equivalents and short term investments increased

$4.5 million to $8.4, principally as a result of the sale of Vermed

-- Bank debt of $1.7 million was retired during in 2007

Additional Key Operating Milestones for the Fourth Qu
'/>"/>

SOURCE CardioDynamics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. CardioDynamics Announces Third Quarter 2007 Conference Call and Webcast
2. CardioDynamics Announces Strategic Alliance With Leading Medical Equipment Manufacturer in India
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. Haemacure Reports Third Quarter 2007 Results
5. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
6. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
7. MDS Reports Third Quarter 2007 Results
8. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Studies show dramatic decline in rheumatoid vasculitis in US veterans 55469 1Studies show dramatic decline in rheumatoid vasculitis in US veterans 55469 2Discovery of natural odors could help develop mosquito repellents 13710 1Discovery of natural odors could help develop mosquito repellents 13710 2Discovery of natural odors could help develop mosquito repellents 13710 3Senator Ted Kennedy 3A A Member of the NAMI Family 55466 1Senator Ted Kennedy 3A A Member of the NAMI Family 55466 2